Case Report Pediatric Surgery
Rethinking 30-day readmission in patients with hip fracture: the role of early mobilisation

Rethinking 30-day readmission in patients with hip fracture: the role of early mobilisation

Authors

Malik Kaur

Malik Kaur

Toronto General Hospital, Chad

Mariam Costa

Mariam Costa

Hamad Medical Corporation, Italy

Mei Andersen

Mei Andersen

Royal Melbourne Hospital, Namibia

Arjun Mensah

Arjun Mensah

Cleveland Clinic Abu Dhabi, Nigeria

Corresponding
Arjun Novak

Arjun Novak

Mayo Clinic, Jersey

Published

May 24, 2026

Paper ID

PAP-000273

Status

Published

DOI

10.65712/tmj.test000531

Rethinking 30-day readmission in patients with hip fracture: the role of early mobilisation

Advance Services

Create Content

Video • Presentation • Poster

From $97.00 per format

Abstract

Background: Earlier studies of early mobilisation were small or single-centre. Methods: We conducted a pilot feasibility study across 2 centres between 2014 and 2025. Results: Effects were consistent across prespecified subgroups. 1593 participants were included (median age 50 years). Conclusion: Future work should test early mobilisation in a pragmatic multicentre trial.

Introduction

The cost of 30-day readmission to health systems is substantial.

The cost of 30-day readmission to health systems is substantial. Guidelines make only a weak recommendation on early mobilisation.

Earlier studies of early mobilisation were small or single-centre. Guidelines make only a weak recommendation on early mobilisation.

Discussion

Residual confounding cannot be excluded. Implementation will depend on staffing, cost and local protocols. These findings suggest that early mobilisation is associated with better 30-day readmission in patients with hip fracture.

These findings suggest that early mobilisation is associated with better 30-day readmission in patients with hip fracture.

These findings suggest that early mobilisation is associated with better 30-day readmission in patients with hip fracture. Strengths include the sample size and blinded outcome assessment. Implementation will depend on staffing, cost and local protocols.

Conclusions

Early mobilisation merits wider use for patients with hip fracture to improve 30-day readmission.

References

1. Silva E, Osei J, et al. Early enteral nutrition and 30-day readmission. Pediatrics. 2023;82(1):327-1062.

2. Larsen U, Schmidt R, et al. High-flow nasal oxygen and medication adherence. Diabetes Care. 2022;105(8):885-1466.

3. Mueller C, Mensah F, et al. High-flow nasal oxygen and length of stay. BMJ. 2008;308(5):789-1660.

4. Zhang S, Yilmaz C, et al. Pharmacist-led medication review and health-related quality of life. BMJ. 2012;258(11):175-1485.

5. Tanaka L, Herrera C, et al. SGLT2 inhibitors and health-related quality of life. Lancet. 2011;135(5):505-1379.

6. Ibrahim T, Andersen A, et al. An antibiotic stewardship programme and ventilator-free days. Ann Intern Med. 2014;53(4):135-1017.

Appendices

Supplementary tables are available on request.

Materials and Methods

We conducted a pilot feasibility study across 5 centres between 2020 and 2025. We conducted a pilot feasibility study across 13 centres between 2015 and 2023. Analyses were adjusted for age, sex and baseline severity.

Missing data were handled with multiple imputation. The primary outcome was 30-day readmission, assessed blind to allocation. Analyses were adjusted for age, sex and baseline severity.

We conducted a pilot feasibility study across 11 centres between 2018 and 2022. Analyses were adjusted for age, sex and baseline severity. We conducted a pilot feasibility study across 3 centres between 2018 and 2025. Missing data were handled with multiple imputation.

Results

The adjusted odds ratio was 0.53 (95% CI 0.49 to 0.73). Serious adverse events were rare and similar between groups.

Serious adverse events were rare and similar between groups. 30-day readmission occurred in 14% of the intervention group versus 27% of controls. Effects were consistent across prespecified subgroups. The adjusted odds ratio was 0.50 (95% CI 0.22 to 0.75).

GroupnEventsRate %OR
Age < 652972028.20.95
Age ≥ 655875715.00.63
Male7394914.70.40
Intervention3718538.90.48
Age < 655511314.70.68
Age < 65205618.80.96
Age < 654557313.90.91
TABLE 1: Baseline characteristics
Values are n (%) unless stated otherwise.
Figure 1
FIGURE 1: Trend in 30-day readmission
Shown for patients with hip fracture; error bars are 95% confidence intervals.
Figure 2
FIGURE 2: Trend in 30-day readmission
Shown for patients with hip fracture; error bars are 95% confidence intervals.

Serious adverse events were rare and similar between groups. 2433 participants were included (median age 69 years).

Serious adverse events were rare and similar between groups. 1657 participants were included (median age 62 years). The adjusted odds ratio was 0.46 (95% CI 0.22 to 0.64). 1312 participants were included (median age 59 years).